Press release Fibrinogen and MB
Press release 6, January 2014
FVIII AND FIBRINOGEN RECOVERY AFTER THERAFLEX MB-PLASMA PROCEDURE IS HIGHER WITH PLASMA IMMEDIATELY TREATED FROM WHOLE BLOOD COLLECTION
Macopharma is pleased to inform you that a current publication from the Belgian Red Cross, entitled “FVIII and fibrinogen recovery after THERAFLEX MB-Plasma procedure following plasma source and treatment time” has been recently published in the Transfusion Journal (Blood Transfusion).
The aim of this study was to investigate the effect of plasma source and preparation time on the quality of MB FFP in terms of FVIII and fibrinogen level and recovery.
FACTOR VIII: The results of the FVIII recovery met the requirements of the Belgian legislation (recovery > 50 %). The mean recovery of FVIII after treatment with MB is above 80 %. The results of this study are notably higher than that published by Rock1 (67 %), by Hornsey2 (75 %) and Garwood3 (median between 76 % and 71 %). However they are comparable to that published by Moog4 (85 %).
FIBRINOGEN: Even after treatment fibrinogen is little affected by the different plasma preparation processes.
This study has showed a difference of recovery on both studied factors (factor VIII and fibrinogen) based on plasma source (Whole blood or apheresis). Both recoveries were higher with plasma immediately treated from whole blood collection than with plasma from apheresis collection.
- Rock G. A comparison of methods of pathogen inactivation of FFP. Vox Sang. 2011 Feb;100(2):169-78.
- Hornsey VS, Drummond O, Young D, Docherty A, Prowse CV. A potentially improved approach to methylene blue virus inactivation of plasma: the Maco Pharma Maco-Tronic system. Transfus.Med. 2001 Feb;11(1):31-6.
- Garwood M, Cardigan RA, Drummond O, Hornsey VS, Turner CP, Young D, Williamson LM, Prowse CV. The effect of methylene blue photoinactivation and methylene blue removal on the quality of fresh-frozen plasma. Transfusion 2003 Sep;43(9):1238-47.
- Moog R, Reichenberg S, Hoburg A, Müller N. Quality of methylene blue–treated fresh-frozen plasma stored up to 27 months. Transfusion 2010;50(2):516-8.